GlycoNex (4168.TWO) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · Taiwan · ISIN TW0004168000
GlycoNex financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 14.70 m TWD | 37.86 m TWD |
| Gross profit | 7.32 m TWD | 23.51 m TWD |
| Operating income | -246.12 m TWD | -249.81 m TWD |
| EBIT | -223.97 m TWD | -227.10 m TWD |
| Net income | -229.71 m TWD | -235.23 m TWD |
| Diluted EPS – continuing operations | -2.12 TWD | -2.09 TWD |
Full history since 2017, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Japan and Taiwan. The company's pipeline under the BLA stage consists of SPD8-P, a Prolia biosimilar for the treatment of osteoporosis; and SPD8-R, a Xgeva biosimilar for the treatment of bone cancer metastases. It also develops GNX102, a humanized monoclonal antibody, which is in Phase 1 clinical trials for the treatment of various solid tumor types, such as colorectal, gastric, lung, breast, and pancreatic cancers; GNX1021, an antibody"drug conjugate that has completed the preclinical stage for oncology indications; GNX201-ADC, an antibody drug in the preclinical stage for the treatment of solid tumors; and GNX203, a glycan-directed antibody drug currently in the lead optimization stage for the treatment of solid tumors, including pancreatic, colorectal, and gynecologic cancers. In addition, the company offers technical consulting services for antibody manufacturing; and general investment services. It has a collaboration with Mitsubishi Gas on the development of denosubmab biosimilar SPD8. GlycoNex Incorporation was incorporated in 2001 and is based in New Taipei City, Taiwan.
More stocks
- Family International Gourmet Co., Ltd (7708.TWO)
- Caravel Minerals Ltd (CVV.AX)
- Atlas Energy Public Company Limited (ATLAS.BK)
- Elite Express Holding Inc. (ETS)
- AmpliTech Group, Inc. (AMPG)
- RAONTECH Inc. (418420.KQ)
- LTMH Public Company Limited (LTMH.BK)
- Pinetree Capital Ltd (PNP.TO)
- ViGenCell Inc. (308080.KQ)
- Sung Woo Co.,Ltd (458650.KQ)
- Sajodongaone Co Ltd (008040.KS)
- NFC Corporation (265740.KQ)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.